The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
On the use of mechanistic models for HIV clinical trials
Abstract: Mechanistic models are mathematical models defined according to biological processes and most often based on a set of differential equations. These models have first been applied in HIV infection in mid-nineties revealing the very high turnover of the virus and of the CD4+ T cells. The improvement of statistical methods to estimate parameters has allowed to use this type of models with more sparse data. Here we show how these models can be useful to analyse data from clinical trials evaluating antiretrovirals or immunotherapies. In addition to quantify the effect of an intervention, they provide very good individual predictions. A next step is the use of these models to design new clinical trials or for treatment monitoring. We show applications with real clinical trials involving antiretrovirals and/or exogeneous cytokines.